Findings

What do systematic reviews say?

9 questions · 9 findings · 3 reviews

No studies found 1 · 11.1%GRADE not reported 1 · 11.1%Very low 1 · 11.1%Low 3 · 33.3%Moderate 3 · 33.3%High 0 · 0%

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 3.9 [1.45, 10.51]
1 study · 41 participants
Low

Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus

Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 9.83 [1.32, 72.95]
1 study · 89 participants
Low

Minor adverse events · aAdult women with PCOS

Oral contraceptive pill (OCP) may leads to lower adverse events ‐ Minor compared with metformin combined with OCP (low certainty).

1 finding from 1 review

Minor adverse events · adolescent women with PCOS

The review found no eligible studies for this question.

1 finding from 1 review

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.68 [0.39, 1.17]
1 study · 86 participants
Moderate

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.32 [0.24, 7.19]
1 study · 47 participants
Moderate

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 10.5 [3.26, 33.75]
1 study · 381 participants
Moderate

Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis

1 finding from 1 review

Interventions to reduce Staphylococcus aureus in the management of eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Very low